ASH 2021| over 50% of myeloma patients reach minimal residual disease negativity with Isatuximab in combination with RVd
During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition a study was presented about a phase III trial for treating myeloma. This treatment supports the current three-drug standard of care with a fourth drug, a monoclonal antibody that is designed to fight cancer while also stimulating the immune system. According to results from the first primary endpoint of the phase III trial, the patients that have been newly diagnosed with myeloma…